<p>Levodopa &amp; benserazide is indicated for the treatment of all forms of Parkinson&#39;s syndrome with the exception of medicine-induced parkinsonism. Levodopa &amp; benserazide dispersible is a formulation which is suitable for patients with dysphagia (difficulties in swallowing) or who require a formulation with a more rapid onset of action, e.g. patients suffering from early morning and afternoon akinesia, or who exhibit &quot;delayed on&quot; or &quot;wearing off&quot; phenomena. Levodopa &amp; benserazide HBS is indicated for patients presenting with all types of fluctuations in response, especially those related to fluctuations in plasma levels (i.e. &quot;peak dose dyskinesia&quot; and &quot;end of dose deterioration&quot;) and for better control of nocturnal symptoms. Further experience is required to determine whether it is also advantageous to use Levodopa &amp; benserazide HBS in new Parkinson patients.</p>